Pfizer Reports Positive Data, Priority Review for Talzenna/Xtandi Combo

By Colin Kellaher


Pfizer Inc. on Thursday said a Phase 3 study combining its breast-cancer drug Talzenna with its prostate-cancer drug Xtandi showed a 37% reduction in the risk of disease... | February 16, 2023

Related Keywords

New York ,United States ,Colin Kellaher ,Pfizer ,Pfizer Inc ,Drug Administration ,Dow Jones ,Nc Stock Exchange ,News ,Information ,Press Release ,Y ,Colin ,Kellaher ,N ,Hursday ,Aid ,Hase , ,Study ,Combining ,Its ,Drug ,Talzenna ,Ith ,Xtandi ,Howed ,Reduction ,The ,Risk ,F Pfe Us7170811035 ,